QWF

目录号: GC50531纯度: >96.00%
QWF是一种特异性的MRGPRX2拮抗剂,同时也是NK1受体拮抗剂。

QWF
Cas No.: 126088-82-2
规格价格库存数量操作
1mg¥1,559.00现货
1
5mg¥3,430.00现货
1
10mg¥5,146.00现货
1
25mg¥8,746.00现货
1
50mg¥13,117.00现货
1
100mg¥19,675.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

QWF is a specific antagonist of MRGPRX2 and also an NK1 receptor antagonist[1]. Mas-related G protein-coupled receptor X2 (MRGPRX2) is a receptor expressed primarily on mast cells and sensory neurons, playing an important role in mediating itch and pain sensations[2]. QWF is usually used in research on pain, inflammation, and allergic reactions[3][4].

In vitro, pre-incubation of HMC1 mast cells with QWF (10, 25, and 100mM; 10min) dose-dependently inhibited C48/80-induced degranulation, and significantly suppressed CD63 surface membrane expression and β-hexosaminidase release[5].

In vivo, QWF (20mg/kg/day; i.p.; beginning in the 7th week after surgery for 2 weeks) reversed endometriosis-induced mechanical and thermal hyperalgesia and reduced ectopic lesion volume and weight in wild-type C57BL/6J mice[6]. QWF (500μM; 10μL; intradermal injection) co-administered with lithocholic acid (LCA) reduced the LCA-induced scratching behavior in ICR mice[7].

References:
[1] Hagiwara D, Miyake H, Morimoto H, Murai M, Fujii T, Matsuo M. Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists. J Med Chem. 1992;35(11):2015-2025.
[2] Kuhn H, Kolkhir P, Babina M, et al. Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J Allergy Clin Immunol. 2021;147(2):456-469.
[3] Azimi E, Reddy VB, Shade KC, et al. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight. 2016;1(16):e89362.
[4] Iio K, Kutsumura N, Nagumo Y, et al. Synthesis of unnatural morphinan compounds to induce itch-like behaviors in mice: Towards the development of MRGPRX2 selective ligands. Bioorg Med Chem Lett. 2022;56:128485.
[5] Hermans MAW, van Stigt AC, van de Meerendonk S, et al. Human Mast Cell Line HMC1 Expresses Functional Mas-Related G-Protein Coupled Receptor 2. Front Immunol. 2021;12:625284.
[6] Mao X, Wang J, Ding S, et al. MRGPRX2 Mediates Mast Cell-Induced Endometriosis Pain Through the Sensitization of Sensory Neurons via Histamine/HRH1/TRPV1 Signaling Pathway. FASEB J. 2025;39(13):e70778.
[7] Song MH, Shim WS. Lithocholic Acid Activates Mas-Related G Protein-Coupled Receptors, Contributing to Itch in Mice. Biomol Ther (Seoul). 2022;30(1):38-47.

QWF是一种特异性的MRGPRX2拮抗剂,同时也是NK1受体拮抗剂[1]。Mas-related G protein-coupled receptor X2(MRGPRX2)是一种主要在肥大细胞和感觉神经元上表达的受体,在介导瘙痒和疼痛感觉中起关键作用[2]。QWF通常用于疼痛、炎症和过敏反应的研究[3][4]

体外实验中,用QWF(10、25和100mM)预孵育HMC1肥大细胞10分钟,可剂量依赖性地抑制C48/80诱导的脱颗粒,并显著抑制CD63表面膜表达和β-己糖胺酶的释放[5]

体内实验中,QWF(20mg/kg/天;腹腔注射;从手术后第7周开始,连续2周)可逆转野生型C57BL/6J小鼠子宫内膜异位症引起的机械性超敏和热超敏反应,并减少异位病灶的体积和重量[6]。QWF (500μM;10μL;皮内注射)与石胆酸(LCA)共给药可减少LCA诱导的ICR小鼠抓挠行为[7]

实验参考方法 Experimental Reference Method

Cell experiment [1]:

Cell lines

HMC1 mast cells

Preparation Method

HMC1 cells were cultured in Roswell Park Memorial Institute medium supplemented with HEPES, 10% inactivated fetal calf serum (FCS), 50μM β‐mercapto‐ethanol, and 1% antibiotics (penicillin/streptomycin). Stimulation experiments were performed using the MRGPRX2 specific ligand compound 48/80 (1-100mg/ml). To further prove the functionality and specificity of MRGPRX2 activation, additional inhibition experiments were conducted by pre-incubation with the MRGPRX2 specific antagonist QWF for 10 minutes, at concentrations of 10, 25 and 100mM. An unstimulated condition containing an equal amount of the QWF diluent, dimethyl sulfoxide (DMSO), was included in every experiment as a control condition, not exceeding the maximal concentration of 0.28% DMSO during stimulation of the cells. Degranulation was assessed by β-hexosaminidase release and CD63 expression.

Reaction Conditions

10, 25, and 100mM; 10min

Applications

Pre-incubation of HMC1 mast cells with QWF dose-dependently inhibited C48/80-induced degranulation, and significantly suppressed CD63 surface membrane expression and β-hexosaminidase release.
Animal experiment [2]:

Animal models

female C57BL/6J wild-type mice

Preparation Method

Six to eight-week-old female C57BL/6J wild-type control mice were housed under identical conditions, with a maximum of 5 animals per cage, on a 12-hour light–dark cycle. Food and water were provided ad libitum. Endometriosis was induced as follows: bilateral ovariectomy was performed seven days before the operation, followed by subcutaneous injection of 0.5mg of oestradiol benzoate dissolved in 60mL of corn oil every 5 days. On Day 0, the uterine tissue of each donor was dissected and cut into fragments less than 1mm3 in size. These fragments were then suspended in 0.9% sterile saline and injected intraperitoneally into two other recipient mice. The Sham operation group received an equivalent volume of 0.9% sterile saline. WT mice were separated into three groups to investigate the role of Mrgprb2 in endometriosis-induced hyperalgesia: the Sham group, drug groups, and the control group. The mice in the Sham and control groups were injected intraperitoneally with the vehicle control containing 10% DMSO, 40% PEG400, 5% Tween-80 and 45% saline, while those in the drug administration group were injected with the Mrgprb2 antagonist QWF (i.p.) at a dose of 20mg/kg once a day. Behavioral tests, including mechanical and thermal paw withdrawal tests and reflexive withdrawal tests to mechanical and thermal stimulation of the abdominal area, were performed to assess hyperalgesia in the mice before and every week after surgery. The mice were anesthetized via the inhalation of CO2 and euthanized via cervical dislocation on Days 28 or 49 after the induction of endometriosis. The peritoneal fluid and DRG (T11-L2 segment) were preserved for further experiments.

Dosage form

20mg/kg/day; i.p. beginning in the 7th week after surgery for 2 weeks

Applications

QWF reversed endometriosis-induced mechanical and thermal hyperalgesia and reduced ectopic lesion volume and weight in wild-type C57BL/6J mice.

References:
[1] Hermans MAW, van Stigt AC, van de Meerendonk S, et al. Human Mast Cell Line HMC1 Expresses Functional Mas-Related G-Protein Coupled Receptor 2. Front Immunol. 2021;12:625284.
[2] Mao X, Wang J, Ding S, et al. MRGPRX2 Mediates Mast Cell-Induced Endometriosis Pain Through the Sensitization of Sensory Neurons via Histamine/HRH1/TRPV1 Signaling Pathway. FASEB J. 2025;39(13):e70778.

产品文档 Product Documents

Purity:>96.00%

化学性质Chemical Properties

CAS 号
126088-82-2
SMILES
CC(C)(C)OC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CC1=CN(C=O)C2=CC=CC=C12)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1
分子式
C38H43N5O8
分子量
697.78 g/mol
溶解性
10mg/mL in DMSO
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol